<DOC>
	<DOCNO>NCT02105688</DOCNO>
	<brief_summary>This 2-part study . The purpose Part A ass efficacy safety grazoprevir ( MK-5172 ) 100 mg combination elbasvir ( MK-8742 ) 50 mg 12 week treatment chronic HCV GT1 , GT4 , GT6 infection treatment-naïve participant opiate substitution therapy ( OST ) . The primary hypothesis percentage participant receive grazoprevir/elbasvir fixed-dose combination ( FDC ) Immediate Treatment Arm achieve Sustained Virologic Response 12 week end study therapy ( SVR12 ) superior 67 % . In addition , participant receive least 1 dose grazoprevir/elbasvir Part A eligible participate Part B , 3-year observational follow-up .</brief_summary>
	<brief_title>An Efficacy Safety Study Grazoprevir ( MK-5172 ) + Elbasvir ( MK-8742 ) Treatment Chronic Hepatitis C Virus ( HCV ) Genotype ( GT ) 1 , 4 , 6 Infection Treatment-Naïve Participants Who Are Opiate Substitution Therapy ( MK-5172-062 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Documented chronic HCV GT1 , GT4 , GT6 infection evidence GT2 , GT3 , GT5 nontypeable genotype HCV ribonucleic acid ( RNA ) confirm screen lab result prior randomization On opiate substitution therapy ( OST ; methadone , levamethadone , buprenorphine , naloxone , naltrexone ) least 3 month prior screen Treatment naïve HCV therapy Human Immunodeficiency Virus ( HIV ) infect participant enrol study must meet following criterion : Documented HIV infection Naïve treatment antiretroviral therapy ( ART ) OR HIV ART least 8 week prior study entry use dual nucleoside reverse transcriptase inhibitor ( NRTI ) backbone tenofovir abacavir either emtricitabine lamivudine PLUS raltegravir ( dolutegravir rilpivirine ) . Dose modification change ART 4 week prior study entry ( Day 1 ) permit Cluster differentiation 4 ( CD4+ ) Tcell count &gt; 200 cells/mm^3 ART &gt; 500 cell/mm^3 ART treatment naïve Undetectable plasma HIV1 RNA least 8 week prior screen ART &lt; 50,000 copies/mL ART treatment naïve Participants HIV1 infection ART must least one viable antiretroviral regimen alternative beyond current regimen event HIV virologic failure development antiretroviral drug resistance Females reproductive potential must agree avoid become pregnant receiving study drug 14 day last dose study drug comply one following : ( 1 ) practice abstinence heterosexual activity OR ( 2 ) use ( partner use ) acceptable contraception heterosexual activity Evidence decompensated liver disease For participant cirrhosis , participant ChildPugh Class B C PughTurcotte ( CPT ) score &gt; 6 Is coinfected hepatitis B virus Has cirrhosis liver image within 6 month Day 1 show evidence hepatocellular carcinoma ( HCC ) evaluation HCC Currently use intend use barbiturate treatment period study Is female pregnant breastfeeding , expect conceive donate egg Day 1 anytime treatment , 14 day last dose study medication , longer dictate local regulation Any medical condition require likely require chronic systemic administration corticosteroid , Tumor Necrosis Factor ( TNF ) antagonists , immunosuppressant drug course trial Evidence history chronic hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>